Skip to content

Study of Inactivated Poliovirus Vaccine Given at an Earlier Schedule With Shorter Intervals

Randomized Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00260312
Enrollment
300
Registered
2005-12-01
Start date
2001-08-31
Completion date
2003-01-31
Last updated
2005-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Level of Immunity Against Poliovirus Infection

Keywords

inactived, polio, vaccine, cuba, trial, randomized, eradication

Brief summary

The purpose of this study was to evaluated the effectiveness of inactivated poliovirus vaccine at a vaccine schedule that is commonly used in developing countries. The effectiveness of inactivated poliovaccine given at this schedule is important to national policy makers as they consider vaccination policies after the use of oral polio vaccine is discontinued.

Detailed description

After polio eradication, access to live polioviruses will be highly restricted, and oral poliovirus vaccine (OPV) use must be discontinued. OPV-using countries must decide whether to switch to inactivated poliovirus vaccine (IPV) or stop polio vaccination. Because only limited data are available on IPV immunogenicity in tropical developing countries, we conducted a randomized controlled trial of IPV in Cuba. The objectives of this study were to assess the humoral and mucosal immunogenicity conferred by IPV administered at the WHO-EPI schedule (6,10,14 wks of age) vs. placebo. A third arm was added to evaluate the immunogenicity of IPV administered at 2 and 4 months of age. Antibody titers were measured prior to the first dose as well as 1 month after the last dose in each study arm. Target sample size was 100 children in each arm. Mucosal (intestinal immunity) was measured indirectly through assessing poliovirus excretion in each group after a natural challenge of trivalent oral polio vaccine (OPV)recieved by study participants through their participation in the annual OPV mass campaigns approximately 1 month after their last dose of vaccine.

Interventions

BIOLOGICALInactivated Polio Vaccine given at an accelerated schedule

Sponsors

World Health Organization
CollaboratorOTHER
Institute Pedro Kouri, Ministry of Public Health (Cuba)
CollaboratorUNKNOWN
Centers for Disease Control and Prevention
CollaboratorFED
Pan American Health Organization
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
MALE
Age
6 Weeks to 2 Months
Healthy volunteers
Yes

Inclusion criteria

Infants born 18 - 20 weeks prior to the first round of the 2002 National Immunization Days in cuba (in March 2002). Born healthy at one of the 4 designated maternity hospitals in Cuba

Exclusion criteria

Serious congenital defect/disease at birth \-

Design outcomes

Primary

MeasureTime frame
Seroconversion by measuring level of poliovirus antibodies in serum. Also, measure of virus titer in stools to indirectly assess the level of intestinal mucosal immunity

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 7, 2026